CORAL GABLES, Fla., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 16,428,572 shares of its common stock in the offering, which included 2,142,857 shares that were issued upon the full exercise by the underwriters of their over-allotment option, at an offering price of $3.50 per share.
Piper Jaffray & Co. acted as the lead bookrunner. SunTrust Robinson Humphrey, Inc. also acted as a bookrunner. H.C. Wainwright & Co. acted as lead manager and Roth Capital Partners acted as co-manager for the offering.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse® is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.